New pancreatic cancer drug regimen shows 'impressive' results in clinical trial
The Parker Institute for Cancer Immunotherapy, funded by Napster founder and billionaire Sean Parker, on Sunday presented the results of clinical trials testing a new treatment for metastatic pancreatic cancer. The results, presented at the annual meeting of the American Association of Cancer Research in Atlanta, Georgia, came just a year and a half after the first patient was enrolled in the trial — "moving fast" by pharmaceutical standards, said Ramy Ibrahim, the Parker Institute's chief medical officer.
The findings show partial tumor shrinkage in metastatic pancreatic cancer patients who'd had no cancer treatment before the multi-drug regimen the trial was testing, Stat News reported Monday. Pancreatic cancer is the third deadliest type of cancer, which makes these early findings "impressive," said the investigator in charge of the trial, Robert Vonderheide.
In addition to the standard drugs typically prescribed for pancreatic cancer, patients were given a third drug, an "experimental antibody" called APX005M. And half of the patients in the trial were also given a fourth drug: Optivo, typically prescribed for lung cancer patients. Patients who received all four drugs had the best results, with 54 percent of them seeing tumor shrinkage that lasted up to 10 months or more.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
With the Phase 1 trial complete, this new regimen will undergo further testing from the Parker Institute before it can move ahead to potentially become a viable treatment for pancreatic cancer patients. Read more about the trial results at Stat News.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Shivani is the editorial assistant at TheWeek.com and has previously written for StreetEasy and Mic.com. A graduate of the physics and journalism departments at NYU, Shivani currently lives in Brooklyn and spends free time cooking, watching TV, and taking too many selfies.
-
Last hopes for justice for UK's nuclear test veterans
Under the Radar Thousands of ex-service personnel say their lives have been blighted by aggressive cancers and genetic mutations
By Sorcha Bradley, The Week UK Published
-
'It may not be surprising that creative work is used without permission'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
5 simple items to help make your airplane seat more comfortable
The Week Recommends Gel cushions and inflatable travel pillows make a world of difference
By Catherine Garcia, The Week US Published
-
Nobody seems surprised Wagner's Prigozhin died under suspicious circumstances
Speed Read
By Peter Weber Published
-
Western mountain climbers allegedly left Pakistani porter to die on K2
Speed Read
By Justin Klawans Published
-
'Circular saw blades' divide controversial Rio Grande buoys installed by Texas governor
Speed Read
By Peter Weber Published
-
Los Angeles city workers stage 1-day walkout over labor conditions
Speed Read
By Justin Klawans Published
-
Mega Millions jackpot climbs to an estimated $1.55 billion
Speed Read
By Catherine Garcia Published
-
Bangladesh dealing with worst dengue fever outbreak on record
Speed Read
By Catherine Garcia Published
-
Glacial outburst flooding in Juneau destroys homes
Speed Read
By Catherine Garcia Published
-
Scotland seeking 'monster hunters' to search for fabled Loch Ness creature
Speed Read
By Justin Klawans Published